TSS
UNCY icon

Two Sigma Securities’s Unicycive Therapeutics UNCY Stock Holding History

Two Sigma Securities’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,204
Closed -$6.92K – 2106
2025
Q1 		$6.92K Buy
+1,204
New +$7.34K ﹤0.01% 1275
2024
Q4 		– Sell
-2,327
Closed -$9.49K – 3223
2024
Q3 		$9.49K Buy
+2,327
New +$9.35K ﹤0.01% 2597
2023
Q4 		– Sell
-1,117
Closed -$9.6K – 3608
2023
Q3 		$9.6K Buy
+1,117
New +$10.5K ﹤0.01% 2700

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Securities's UNCY Position: Q2 2025 in Review

Two Sigma Securities sold out of Unicycive Therapeutics (UNCY) in Q2 2025, closing a stake of 1,204 shares — an estimated $6.92K sold.

Two Sigma Securities first reported a position in UNCY in Q3 2023 and held it in 3 quarters. The position peaked at $9.6K in Q3 2023. 20 funds tracked by Wall St. Rank hold UNCY as of Q2 2025.

  • Two Sigma Securities reported no remaining Unicycive Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Securities sold 1,204 Unicycive Therapeutics shares in Q2 2025, an estimated $6.92K.
  • Two Sigma Securities first reported a position in Unicycive Therapeutics in Q3 2023 and held it in 3 quarters.
  • Two Sigma Securities's Unicycive Therapeutics position peaked at $9.6K in Q3 2023.
  • 20 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.